Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 89
Filter
1.
J Gen Virol ; 102(4)2021 04.
Article in English | MEDLINE | ID: mdl-33830908

ABSTRACT

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and more than a million deaths. The infection causes COVID-19, a disease of the respiratory system of divergent severity. No treatment exists. Epigallocatechin-3-gallate (EGCG), the major component of green tea, has several beneficial properties, including antiviral activities. Therefore, we examined whether EGCG has antiviral activity against SARS-CoV-2. EGCG blocked not only the entry of SARS-CoV-2, but also MERS- and SARS-CoV pseudotyped lentiviral vectors and inhibited virus infections in vitro. Mechanistically, inhibition of the SARS-CoV-2 spike-receptor interaction was observed. Thus, EGCG might be suitable for use as a lead structure to develop more effective anti-COVID-19 drugs.


Subject(s)
Antiviral Agents/pharmacology , Catechin/analogs & derivatives , SARS-CoV-2/drug effects , Tea/chemistry , Animals , Betacoronavirus/drug effects , Betacoronavirus/physiology , COVID-19/prevention & control , COVID-19/virology , Catechin/pharmacology , Cell Survival/drug effects , Chlorocebus aethiops , HEK293 Cells , Humans , Lentivirus/drug effects , Lentivirus/genetics , SARS-CoV-2/physiology , Spike Glycoprotein, Coronavirus/genetics , Vero Cells , Virus Attachment/drug effects , Virus Replication/drug effects
2.
Life Sci ; 272: 119269, 2021 May 01.
Article in English | MEDLINE | ID: mdl-33631175

ABSTRACT

AIMS: Our previous study showed that intravitreal delivery of self-complementary AAV2 (scAAV2)-mediated exoenzyme C3 transferase (C3) can attenuate retinal ischemia/reperfusion (I/R) injury. The current study investigated the neuroprotective effects of lentivirus (LV)-mediated C3 transgene expression on rat retinal I/R injury. MAIN METHODS: The LV encoding C3 and green fluorescent protein (GFP) together (LV-C3-GFP) or GFP only (LV-GFP) was intravitreally injected to SPRAGUE-DAWLEY rats. On day 5 post-intravitreal injection, eyes were evaluated by slit-lamp examination. The GFP expression on retina was confirmed by in vivo and ex vivo assessments. RhoA GTPase expression in retina was examined by western blot. Retinal I/R injury was generated by transiently increasing intraocular pressure (110 mmHg, 90 min). Eyes were then enucleated, and retinas processed for morphological analysis and TdT-dUTP terminal nick-end labeling (TUNEL) assay. KEY FINDINGS: No obvious inflammatory reactions or surgical complications were observed after intravitreal injection of LV vectors. There was a significant decrease of total RhoA GTPase level in the retina treated with LV-C3-GFP. Compared to the blank control group, LV-C3-GFP and LV-GFP did not affect the retinal thickness, cell density in ganglion cell layer (GCL), or numbers of apoptotic cells in retinal flat-mounts. In the LV-GFP-treated retinas, I/R decreased the retinal thickness and GCL cell density and increased apoptotic retinal cell numbers. LV-C3-GFP significantly protected against all these degenerative effects of I/R. SIGNIFICANCE: This study indicated that LV-mediated C3 transgene expression exhibits neuroprotective effects on the retinal I/R injury and holds potential as a novel neuroprotective approach targeting certain retinopathies.


Subject(s)
ADP Ribose Transferases/pharmacology , Botulinum Toxins/pharmacology , Reperfusion Injury/therapy , ADP Ribose Transferases/metabolism , Animals , Apoptosis/drug effects , Botulinum Toxins/metabolism , Cell Survival/drug effects , Green Fluorescent Proteins/metabolism , Intraocular Pressure/drug effects , Ischemia/metabolism , Ischemia/therapy , Lentivirus/genetics , Lentivirus/metabolism , Male , Neuroprotective Agents/pharmacology , Rats , Rats, Sprague-Dawley , Reperfusion Injury/metabolism , Retina/metabolism , Retinal Diseases/metabolism , Retinal Diseases/therapy , Retinal Ganglion Cells/metabolism
3.
Viruses ; 13(2)2021 01 24.
Article in English | MEDLINE | ID: mdl-33498923

ABSTRACT

The 3C-like protease (3CLpro) of SARS-CoV-2 is considered an excellent target for COVID-19 antiviral drug development because it is essential for viral replication and has a cleavage specificity distinct from human proteases. However, drug development for 3CLpro has been hindered by a lack of cell-based reporter assays that can be performed in a BSL-2 setting. Current efforts to identify 3CLpro inhibitors largely rely upon in vitro screening, which fails to account for cell permeability and cytotoxicity of compounds, or assays involving replication-competent virus, which must be performed in a BSL-3 facility. To address these limitations, we have developed a novel cell-based luciferase complementation reporter assay to identify inhibitors of SARS-CoV-2 3CLpro in a BSL-2 setting. The assay is based on a lentiviral vector that co-expresses 3CLpro and two luciferase fragments linked together by a 3CLpro cleavage site. 3CLpro-mediated cleavage results in a loss of complementation and low luciferase activity, whereas inhibition of 3CLpro results in 10-fold higher levels of luciferase activity. The luciferase reporter assay can easily distinguish true 3CLpro inhibition from cytotoxicity, a powerful feature that should reduce false positives during screening. Using the assay, we screened 32 small molecules for activity against SARS-CoV-2 3CLpro, including HIV protease inhibitors, HCV protease inhibitors, and various other compounds that have been reported to inhibit SARS-CoV-2 3CLpro. Of these, only five exhibited significant inhibition of 3CLpro in cells: GC376, boceprevir, Z-FA-FMK, calpain inhibitor XII, and GRL-0496. This assay should greatly facilitate efforts to identify more potent inhibitors of SARS-CoV-2 3CLpro.


Subject(s)
Antiviral Agents/metabolism , Coronavirus 3C Proteases/antagonists & inhibitors , Luciferases/metabolism , Protease Inhibitors/metabolism , SARS-CoV-2/enzymology , Antiviral Agents/pharmacology , Cell Survival/drug effects , Coronavirus 3C Proteases/genetics , Coronavirus 3C Proteases/metabolism , Drug Evaluation, Preclinical , HEK293 Cells , Humans , Lentivirus/genetics , Luciferases/genetics , Protease Inhibitors/pharmacology
4.
J Virol ; 95(3)2021 01 13.
Article in English | MEDLINE | ID: mdl-33173010

ABSTRACT

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has caused a pandemic of historic proportions and continues to spread globally, with enormous consequences to human health. Currently there is no vaccine, effective therapeutic, or prophylactic. As with other betacoronaviruses, attachment and entry of SARS-CoV-2 are mediated by the spike glycoprotein (SGP). In addition to its well-documented interaction with its receptor, human angiotensin-converting enzyme 2 (hACE2), SGP has been found to bind to glycosaminoglycans like heparan sulfate, which is found on the surface of virtually all mammalian cells. Here, we pseudotyped SARS-CoV-2 SGP on a third-generation lentiviral (pLV) vector and tested the impact of various sulfated polysaccharides on transduction efficiency in mammalian cells. The pLV vector pseudotyped SGP efficiently and produced high titers on HEK293T cells. Various sulfated polysaccharides potently neutralized pLV-S pseudotyped virus with clear structure-based differences in antiviral activity and affinity to SGP. Concentration-response curves showed that pLV-S particles were efficiently neutralized by a range of concentrations of unfractionated heparin (UFH), enoxaparin, 6-O-desulfated UFH, and 6-O-desulfated enoxaparin with 50% inhibitory concentrations (IC50s) of 5.99 µg/liter, 1.08 mg/liter, 1.77 µg/liter, and 5.86 mg/liter, respectively. In summary, several sulfated polysaccharides show potent anti-SARS-CoV-2 activity and can be developed for prophylactic as well as therapeutic purposes.IMPORTANCE The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Wuhan, China, in late 2019 and its subsequent spread to the rest of the world has created a pandemic situation unprecedented in modern history. While ACE2 has been identified as the viral receptor, cellular polysaccharides have also been implicated in virus entry. The SARS-CoV-2 spike glycoprotein (SGP) binds to glycosaminoglycans like heparan sulfate, which is found on the surface of virtually all mammalian cells. Here, we report structure-based differences in antiviral activity and affinity to SGP for several sulfated polysaccharides, including both well-characterized FDA-approved drugs and novel marine sulfated polysaccharides, which can be developed for prophylactic as well as therapeutic purposes.


Subject(s)
Antiviral Agents/pharmacology , Heparin/pharmacology , SARS-CoV-2/drug effects , Virus Internalization/drug effects , Animals , Antiviral Agents/chemistry , Antiviral Agents/metabolism , Drug Evaluation, Preclinical , Enoxaparin/chemistry , Enoxaparin/metabolism , Enoxaparin/pharmacology , Genetic Vectors/genetics , HEK293 Cells , Heparin/chemistry , Heparin/metabolism , Heparitin Sulfate/metabolism , Humans , Inhibitory Concentration 50 , Lentivirus/genetics , Molecular Structure , Molecular Weight , Polysaccharides/chemistry , Polysaccharides/metabolism , Polysaccharides/pharmacology , Protein Binding , SARS-CoV-2/physiology , Spike Glycoprotein, Coronavirus/genetics , Spike Glycoprotein, Coronavirus/metabolism , Transduction, Genetic , Virus Attachment/drug effects
5.
Viruses ; 12(5)2020 05 25.
Article in English | MEDLINE | ID: mdl-32466195

ABSTRACT

HIV-1 infection is a complex, multi-step process involving not only viral, but also multiple cellular factors. To date, drug discovery methods have primarily focused on the inhibition of single viral proteins. We present an efficient and unbiased approach, compatible with biosafety level 1 (BSL-1) conditions, to identify inhibitors of HIV-1 reverse transcription, intracellular trafficking, nuclear entry and genome integration. Starting with a fluorescent assay setup, we systematically improved the screening methodology in terms of stability, efficiency and pharmacological relevance. Stability and throughput were optimized by switching to a luciferase-based readout. BSL-1 compliance was achieved without sacrificing pharmacological relevance by using lentiviral particles pseudo-typed with the mouse ecotropic envelope protein to transduce human PM1 T cells gene-modified to express the corresponding murine receptor. The cellular assay was used to screen 26,048 compounds selected for maximum diversity from a 200,640-compound in-house library. This yielded z' values greater than 0.8 with a hit rate of 3.3% and a confirmation rate of 50%. We selected 93 hits and enriched the collection with 279 similar compounds from the in-house library to identify promising structural features. The most active compounds were validated using orthogonal assay formats. The similarity of the compound profiles across the different platforms demonstrated that the reported lentiviral assay system is a robust and versatile tool for the identification of novel HIV-1 inhibitors.


Subject(s)
Drug Evaluation, Preclinical/methods , Genetic Vectors , HIV-1/drug effects , High-Throughput Screening Assays/methods , Lentivirus/genetics , Animals , Anti-HIV Agents/pharmacology , Cell Line , Containment of Biohazards , Drug Development , Drug Discovery , HEK293 Cells , Humans , Mice , Viral Envelope Proteins , Virion
6.
Anal Chem ; 92(5): 3972-3980, 2020 03 03.
Article in English | MEDLINE | ID: mdl-32045214

ABSTRACT

Membrane proteins (MPs) are playing important roles in several biological processes. Screening new candidate compounds targeting MPs is important for drug discovery. However, it remains challenging to characterize the interactions between MPs and small-molecule ligands in a label-free method. In this study, a surface plasmon resonance (SPR)-based membrane protein-targeted active ingredients recognition strategy was constructed. This strategy contains two major modules: affinity detection module and ligand screening module. Through the combination of these two functional modules, it is feasible to screen small molecular ligands targeting MPs from herbal medicines. First, we have constructed high/low comparative C-X-C chemokine receptor type 4 (CXCR4)-expressed lentiviral particles (LVPs) models and characterized the expression levels. Then we immobilized LVPs on CM5 chips and detected the affinity between AMD3100 and CXCR4 by using affinity detection module. The KD of AMD3100 was 32.48 ± 3.17 nM. Furthermore, the suitability and robustness of the ligand screening module were validated by using AMD3100 as a positive compound. Subsequently, this module was applied in the screening of CXCR4 small molecular ligands from herbal medicine extracts. Senkyunolide I was screened out from Chuanxiong extract. The affinity constant between senkyunolide I and CXCR4 was 2.94 ± 0.36 µM. The Boyden chamber assay revealed that senkyunolide I could inhibit cell migration process. In conclusion, an SPR-based small molecular ligand recognition strategy combined with virus-based membrane protein stabilization method was constructed. The SPR-based membrane protein-targeted active ingredients recognition strategy will be an effective tool to screen target components from complex systems acting on MPs.


Subject(s)
Ligands , Membrane Proteins/chemistry , Plants, Medicinal/chemistry , Surface Plasmon Resonance/methods , Benzofurans/chemistry , Benzofurans/metabolism , Benzylamines , Cyclams , Drugs, Chinese Herbal/chemistry , HEK293 Cells , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/metabolism , Humans , Lentivirus/genetics , Plants, Medicinal/metabolism , Protein Binding , RNA Interference , RNA, Small Interfering/metabolism , Receptors, CXCR4/antagonists & inhibitors , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , Virion/chemistry
7.
Neurochem Res ; 44(12): 2796-2808, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31728858

ABSTRACT

The role of potassium channels provides suggestive evidence for the etiology of autism. The voltage-gated potassium channel Kv10.2 (KCNH5) is widely expressed in the brain. However, the inherent relationship between Kv10.2 and autism is still unclear. Herein, a rat valproic acid (VPA)-induced autism spectrum disorder model was established. The expression level of Kv10.2 was obviously decreased in the hippocampus of VPA rats. Kv10.2 was mainly localized in neurons. Subsequently, a recombinant lentivirus expressing Kv10.2 was used to upregulate the expression of Kv10.2 in the hippocampus of VPA-exposed rats. The results were promising as injection of the Kv10.2 lentivirus in the hippocampus relieved anxiety and stereotypical behavior, and improved the social and exploratory abilities of rats that were prenatally exposed to VPA. In addition, spectral analysis of electroencephalogram data revealed that animals exposed to VPA exhibited increased high-frequency activity compared with the control rats, and this activity recovered to a certain extent after upregulation of Kv10.2 expression by lentivirus injection. These results suggest that changes in Kv10.2 may play an important role in the etiology of autism, thus providing a promising direction for further research on autism.


Subject(s)
Autistic Disorder/therapy , Ether-A-Go-Go Potassium Channels/metabolism , Ether-A-Go-Go Potassium Channels/therapeutic use , Hippocampus/metabolism , Animals , Anxiety/metabolism , Autistic Disorder/chemically induced , Autistic Disorder/etiology , Behavior, Animal/physiology , Biological Therapy , Ether-A-Go-Go Potassium Channels/genetics , Female , Hippocampus/pathology , Lentivirus/genetics , Male , Pregnancy , Rats , Valproic Acid
8.
Br J Anaesth ; 123(4): 439-449, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31383364

ABSTRACT

BACKGROUND: Nerve growth factor (NGF) has been implicated in hyperalgesia by sensitising nociceptors. A role for NGF in modulating myocardial injury through ischaemic nociceptive signalling is plausible. We examined whether inhibition of spinal NGF attenuates myocardial ischaemia-reperfusion injury and explored the underlying mechanisms. METHODS: In adult rats, lentivirus-mediated short-hairpin RNA targeted at reducing NGF gene expression (NGF-shRNA) or a transient receptor potential vanilloid 1 (TRPV1) antagonist (capsazepine) was injected intrathecally before myocardial ischaemia-reperfusion. Infarct size (expressed as the ratio of area at risk) and risk of arrhythmias were quantified. Whole-cell clamp patch electrophysiology was used to record capsaicin currents in primary dorsal root ganglion neurones. The co-expression of substance P (SP) and calcitonin gene-related peptide (CGRP), plus activation of TRPV1, protein kinase B (Akt) and extracellular signal-regulated kinase (ERK) were also quantified. RESULTS: NGF levels increased by 2.95 (0.34)-fold in dorsal root ganglion and 2.12 (0.27)-fold in spinal cord after myocardial ischaemia-reperfusion injury. Intrathecal injection of NGF-shRNA reduced infarct area at risk from 0.58 (0.02) to 0.37 (0.02) (P<0.01) and reduced arrhythmia score from 3.67 (0.33) to 1.67 (0.33) (P<0.01). Intrathecal capsazepine was similarly cardioprotective. NGF-shRNA suppressed expression of SP/CGRP and activation of Akt/ERK and TRPV1 in spinal cord. NGF increased capsaicin current amplitude from 144 (42) to 840 (132) pA (P<0.05), which was blocked by the TRPV1 antagonist 5'-iodoresiniferatoxin. Exogenous NGF enhanced capsaicin-induced Akt/ERK and TRPV1 activation in PC12 neuroendocrine tumour cells in culture. CONCLUSIONS: Spinal NGF contributes to myocardial ischaemia-reperfusion injury by mediating nociceptive signal transmission.


Subject(s)
Genetic Therapy/methods , Lentivirus/genetics , Myocardial Reperfusion Injury/genetics , Myocardial Reperfusion Injury/prevention & control , Nerve Growth Factor/genetics , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/therapeutic use , Animals , Arrhythmias, Cardiac/prevention & control , Capsaicin/analogs & derivatives , Capsaicin/pharmacology , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/therapeutic use , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Injections, Spinal , MAP Kinase Signaling System/drug effects , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/prevention & control , Nerve Growth Factor/biosynthesis , PC12 Cells , Patch-Clamp Techniques , Rats , Rats, Sprague-Dawley , TRPV Cation Channels/antagonists & inhibitors , TRPV Cation Channels/metabolism
9.
Sci Rep ; 9(1): 7927, 2019 05 28.
Article in English | MEDLINE | ID: mdl-31138824

ABSTRACT

Obesity has become a worldwide epidemic. We have previously reported that systemic administration of pNaKtide which targets the Na/K-ATPase oxidant amplification loop (NKAL) was able to decrease systemic oxidative stress and adiposity in mice fed a high fat and fructose supplemented western diet (WD). As adipocytes are believed to play a central role in the development of obesity and its related comorbidities, we examined whether lentiviral-mediated adipocyte-specific expression of NaKtide, a peptide derived from the N domain of the alpha1 Na/K-ATPase subunit, could ameliorate the effects of the WD. C57BL6 mice were fed a WD, which activated Na/K-ATPase signaling in the adipocytes and induced an obese phenotype and caused an increase in plasma levels of leptin, IL-6 and TNFα. WD also decreased locomotor activity, expression of the D2 receptor and tyrosine hydroxylase in brain tissue, while markers of neurodegeneration and neuronal apoptosis were increased following the WD. Selective adipocyte expression of NaKtide in these mice fed a WD attenuated all of these changes including the brain biochemical alterations and behavioral adaptations. These data suggest that adipocyte derived cytokines play an essential role in the development of obesity induced by a WD and that targeting the adipocyte NKAL loop may serve as an effective therapeutic strategy.


Subject(s)
Adipocytes/metabolism , Diet, Western/adverse effects , Obesity/genetics , Peptide Fragments/genetics , Sodium-Potassium-Exchanging ATPase/genetics , Adiposity , Animals , Disease Models, Animal , Enzyme Activation , Gene Expression , Lentivirus/genetics , Male , Mice, Inbred C57BL , Obesity/metabolism , Oxidative Stress , Peptide Fragments/metabolism , Signal Transduction , Sodium-Potassium-Exchanging ATPase/metabolism
10.
Eur J Pharmacol ; 844: 65-72, 2019 Feb 05.
Article in English | MEDLINE | ID: mdl-30529106

ABSTRACT

Fibroblast-like synoviocytes in rheumatoid arthritis (RA-FLSs) play a key role in cartilage destruction. We previously found that resveratrol (Res) could promote FLSs apoptosis in adjuvant arthritis rats, but the underlying mechanism was unclear. According to our latest study, Res can suppress the expression of mitochondrial superoxide dismutase (MnSOD) and RA-FLSs proliferation. It was associated with elevated mitochondrial reactive oxygen species levels. Therefore, we hypothesized that Res-mediated RA-FLSs apoptosis might occur via the MnSOD- mitochondrial reactive oxygen species pathway. RA-FLSs were infected with lentiviruses and screened with puromycin at a concentration of 8 µg/ml. We divided the RA-FLSs into four groups: a control group, a negative control (NC) group, a MnSOD overexpression group, and a MnSOD RNAi group. The four groups of RA-FLSs were tested using confocal laser scanning microscopy, CCK-8 assays, flow cytometry, and western blotting were conducted to determine the involvement of the MnSOD-mitochondrial reactive oxygen species pathway. Compared with the NC group, the MnSOD overexpression group treated with different concentrations of Res (0, 25, 50, 100, or 200 µM) and 5 µM H2O2 showed reduced levels of mitochondrial reactive oxygen species, increased B-cell-lymphoma-2 (Bcl-2), reduced Bcl-2 Associated X protein (Bax), and fewer apoptotic cells. The MnSOD RNAi group showed the opposite results. Thus, we concluded that Res could facilitate RA-FLSs apoptosis by regulating MnSOD expression and mitochondrial reactive oxygen species levels. Our findings show a novel mechanism for the beneficial effects of Res, especially in relation to the MnSOD-mitochondrial reactive oxygen species signaling pathway in RA.


Subject(s)
Apoptosis/drug effects , Arthritis, Rheumatoid/metabolism , Lentivirus/genetics , Resveratrol/pharmacology , Superoxide Dismutase/genetics , Synoviocytes/drug effects , Cell Line , Cell Proliferation/drug effects , Fibroblasts , Gene Silencing , Humans , Mitochondria/metabolism , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism , Synoviocytes/metabolism
11.
Cell Reprogram ; 20(5): 289-300, 2018 10.
Article in English | MEDLINE | ID: mdl-30277824

ABSTRACT

Establishing pig embryonic stem cells (pESCs) remains a challenge due to differences in the genetic backgrounds of mouse, human, and pig. Therefore, pig-specific pluripotency markers and cellular signaling must be identified. In this study, doxycycline (DOX)-inducible vectors carrying Oct4, sex-determining region Y-box 2 (Sox2), Nanog, Kruppel-like family 4 (Klf4), or Myc, which are known reprogramming factors, were transduced into pESCs. And pluripotency genes were analyzed in one or two reprogramming factor-expressed pESCs. When cultured without DOX, pESCs were stably maintained in basic fibroblast growth factor-supplemented media. However, when treated with DOX, the cells lost their alkaline phosphatase (AP) activity and differentiated within 2 weeks. Subsequently, we investigated the expression of genes related to pluripotency in DOX-treated pESCs using quantitative reverse transcription-polymerase chain reaction (PCR). Expression levels of Oct4, E-cadherin, and Fut4 were significantly increased by Oct4 overexpression, and Oct4 and Fut4 were upregulated in the Sox2-infected group. When a combination of two reprogramming factors, including Oct4 or Sox2, was introduced, weak AP activity remained. In addition, several of the two reprogramming factor transduction groups could be maintained after subculturing with transgene activation. Although long-term culture failed, pESCs transduced with Oct4 and Nanog, Oct4 and Klf4, or Sox2 and Nanog combinations could be subcultured even under transgene activation conditions. Analysis of the cause of long-term culture failure by quantitative PCR confirmed that the expression of intermediate reprogramming markers was not maintained. Given these results, additional methods are needed to support the completion of each reprogramming phase to succeed in the conversion of the pluripotent state of pESCs. This study improves our understanding of pluripotent networks and can be used to aid in the establishment of bona fide pig pluripotent stem cells.


Subject(s)
Cell Differentiation , Cellular Reprogramming , Embryoid Bodies/cytology , Embryonic Stem Cells/cytology , Pluripotent Stem Cells/cytology , Transcription Factors/metabolism , Animals , Cells, Cultured , Embryoid Bodies/metabolism , Embryonic Stem Cells/metabolism , Fucosyltransferases/genetics , Fucosyltransferases/metabolism , Kruppel-Like Factor 4 , Kruppel-Like Transcription Factors/genetics , Kruppel-Like Transcription Factors/metabolism , Lentivirus/genetics , Pluripotent Stem Cells/metabolism , Swine , Transcription Factors/genetics
12.
Hum Gene Ther ; 29(10): 1183-1201, 2018 10.
Article in English | MEDLINE | ID: mdl-30160169

ABSTRACT

Genetically modified, autologous hematopoietic stem and progenitor cells (HSPCs) represent a new class of genetic medicine. Following this therapeutic paradigm, we are developing a product candidate, designated CD68-ET3-LV CD34+, for the treatment of the severe bleeding disorder, hemophilia A. The product consists of autologous CD34+ cells transduced with a human immunodeficiency virus 1-based, monocyte lineage-restricted, self-inactivating lentiviral vector (LV), termed CD68-ET3-LV, encoding a bioengineered coagulation factor VIII (fVIII) transgene, termed ET3, designed for enhanced expression. This vector was shown capable of high-titer manufacture under clinical scale and Good Manufacturing Practice. Biochemical and immunogenicity testing of recombinant ET3, as well as safety and efficacy testing of CD68-ET3-LV HSPCs, were utilized to demonstrate overall safety and efficacy in murine models. In the first model, administration of CD68-ET3-LV-transduced stem-cell antigen-1+ cells to hemophilia A mice resulted in sustained plasma fVIII production and hemostatic correction without signs of toxicity. Patient-derived, autologous mobilized peripheral blood (mPB) CD34+ cells are the clinical target cells for ex vivo transduction using CD68-ET3-LV, and the resulting genetically modified cells represent the investigational drug candidate. In the second model, CD68-ET3-LV gene transfer into mPB CD34+ cells isolated from normal human donors was utilized to obtain in vitro and in vivo pharmacology, pharmacokinetic, and toxicology assessment. CD68-ET3-LV demonstrated reproducible and efficient gene transfer into mPB CD34+ cells, with vector copy numbers in the range of 1 copy per diploid genome equivalent without affecting clonogenic potential. Differentiation of human CD34+ cells into monocytes was associated with increased fVIII production, supporting the designed function of the CD68 promoter. To assess in vivo pharmacodynamics, CD68-ET3-LV CD34+ cell product was administered to immunodeficient mice. Treated mice displayed sustained plasma fVIII levels and no signs of product related toxicity. Collectively, the findings of the current study support the preclinical safety and efficacy of CD68-ET3-LV CD34+.


Subject(s)
Factor VIII/genetics , Genetic Engineering , Genetic Vectors/genetics , Hematopoietic Stem Cells/metabolism , Hemophilia A/genetics , Hemophilia A/therapy , Lentivirus/genetics , Animals , Blood Coagulation , Disease Models, Animal , Drug Evaluation, Preclinical , Female , Gene Expression , Gene Order , Gene Transfer Techniques , Genetic Vectors/administration & dosage , Genetic Vectors/adverse effects , Humans , Male , Mice , Mice, Transgenic , Mutagenesis, Insertional , Swine , Transduction, Genetic , Transgenes , Treatment Outcome , Virus Integration
13.
Methods Mol Biol ; 1836: 139-158, 2018.
Article in English | MEDLINE | ID: mdl-30151572

ABSTRACT

Our understanding of infection biology is based on experiments in which pathogen or host proteins are perturbed by small compound inhibitors, mutation, or depletion. This approach has been remarkably successful, as, for example, demonstrated by the independent identification of the endosomal membrane protein Niemann-Pick C1 as an essential factor for Ebola virus infection in both small compound and insertional mutagenesis screens (Côté, Nature 477:344-348, 2011; Carette et al., Nature 477:340-343, 2011). However, many aspects of host-pathogen interactions are poorly understood because we cannot target all of the involved molecules with small molecules, or because we cannot deplete essential proteins. Single domain antibody fragments expressed in the cytosol or other organelles constitute a versatile alternative to perturb the function of any given protein by masking protein-protein interaction interfaces, by stabilizing distinct conformations, or by directly interfering with enzymatic activities. The variable domains of heavy chain-only antibodies (VHHs) from camelid species can be cloned from blood samples of animals immunized with the desired target molecules. We can thus exploit the ability of the camelid immune system to generate affinity-matured single domain antibody fragments to obtain highly specific tools. Interesting VHH candidates are typically identified based on their affinity toward immobilized antigens using techniques such as phage display.The phenotypical screening approach described here allows the direct identification of VHHs that prevent infection of cells with influenza A virus (IAV) or other pathogens. The VHH repertoire is cloned into a lentiviral vector, which is used to generate pseudo-typed lentivirus particles. Target cells are transduced with the lentivirus, so that every cell inducibly expresses a different VHH. This cell collection is then challenged with a lethal dose of virus. Only the cells which express a VHH that prevents infection by targeting virus proteins or host cell components essential for infection will survive. We can thus identify critical target molecules including vulnerable epitopes and conformations, render target molecules accessible to informative perturbation studies, and stabilize intermediates of virus entry for detailed analysis.


Subject(s)
Anti-Retroviral Agents/pharmacology , Lentivirus/drug effects , Phenotype , Single-Domain Antibodies/pharmacology , Amino Acid Sequence , Cell Line , Drug Evaluation, Preclinical/methods , Gene Library , Genetic Vectors/genetics , Humans , Influenza A virus/genetics , Lentivirus/genetics , Lentivirus Infections/drug therapy , Lentivirus Infections/virology , Microbial Sensitivity Tests , Single-Domain Antibodies/chemistry , Single-Domain Antibodies/genetics
14.
Pharmacology ; 102(3-4): 169-179, 2018.
Article in English | MEDLINE | ID: mdl-30099452

ABSTRACT

In this study, rat and human 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) have been cloned by lentiviral transduction and expressed by CHO-K1 cells. The results showed that recombinant plasmids contained R11bhsd1 or H11bhsd1 have been constructed, which is consistent with the gene bank respectively. A clone cell was selected with G418 and cultivated to express 11ß-HSD1. 11ß-HSD1 catalytic activity of rat and human were 99.5 and 98.7%, respectively, determined by scanning radiometer. And the cloned CHO-K1 cells expressed the protein of 11ß-HSD1 in a long-term and stable manner, which makes it suitable for screening 11ß-HSD1 inhibitor. The three-dimensional structure of 11ß-HSD1 was used for studying the interaction between inhibitor and enzyme by the binding poses predicted by AutoDock and LeDock software. The docking results revealed that compound 8 forms 2 hydrogen bonds with the residues of Gly-216 and Ile-218 in 11ß-HSD1, that is to say compound 8 maybe a good 11ß-HSD1 inhibitor. Moreover, C57BL/6 mice with R11bHsd1 overexpression had a higher body weight, glucose, total cholesterol, and triglyceride levels compared to the mice treated with an empty viral vector. The results might provide a beneficial foundation for selecting inhibitors of 11ß-HSD1 or for researching drug candidate mechanisms.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors , Curcumin/analogs & derivatives , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , 11-beta-Hydroxysteroid Dehydrogenase Type 1/chemistry , 11-beta-Hydroxysteroid Dehydrogenase Type 1/genetics , 11-beta-Hydroxysteroid Dehydrogenase Type 1/metabolism , Animals , CHO Cells , Cloning, Molecular , Cricetinae , Cricetulus , Curcumin/chemical synthesis , Curcumin/pharmacology , Drug Evaluation, Preclinical/methods , Enzyme Inhibitors/chemical synthesis , Lentivirus/genetics , Liver/pathology , Mice , Mice, Inbred C57BL , Molecular Docking Simulation , Transduction, Genetic
15.
PLoS One ; 13(1): e0191570, 2018.
Article in English | MEDLINE | ID: mdl-29385199

ABSTRACT

In the search for novel therapeutic targets, RNA interference screening has become a valuable tool. High-throughput technologies are now broadly accessible but their assay development from baseline remains resource-intensive and challenging. Focusing on this assay development process, we here describe a target discovery screen using pooled shRNA libraries and next-generation sequencing (NGS) deconvolution in a cell line model of Ewing sarcoma. In a strategy designed for comparative and synthetic lethal studies, we screened for targets specific to the A673 Ewing sarcoma cell line. Methods, results and pitfalls are described for the entire multi-step screening procedure, from lentiviral shRNA delivery to bioinformatics analysis, illustrating a complete model workflow. We demonstrate that successful studies are feasible from the first assay performance and independent of specialized screening units. Furthermore, we show that a resource-saving screen depth of 100-fold average shRNA representation can suffice to generate reproducible target hits despite heterogeneity in the derived datasets. Because statistical analysis methods are debatable for such datasets, we created ProFED, an analysis package designed to facilitate descriptive data analysis and hit calling using an aim-oriented profile filtering approach. In its versatile design, this open-source online tool provides fast and easy analysis of shRNA and other count-based datasets to complement other analytical algorithms.


Subject(s)
Drug Discovery/methods , Drug Evaluation, Preclinical/methods , Gene Library , RNA, Small Interfering/genetics , Algorithms , Cell Line, Tumor , Computational Biology , HEK293 Cells , High-Throughput Nucleotide Sequencing , Humans , Lentivirus/genetics , RNA Interference , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/genetics , Sequence Analysis, RNA , Workflow
16.
Cell Physiol Biochem ; 42(4): 1390-1406, 2017.
Article in English | MEDLINE | ID: mdl-28715808

ABSTRACT

BACKGROUND/AIMS: Vitamin A (VA) protects the intestinal epithelial barrier by improving cell migration and proliferation. Our previous studies demonstrated that VA deficiency (VAD) during pregnancy suppresses the systemic and mucosal immune responses in the intestines of offspring and that VA supplementation (VAS) during early life can increase immune cell counts. However, little is known about the mechanisms by which VA regulates intestinal epithelial barrier function. METHODS: Caco-2 cells were treated with all-trans retinoic acid (ATRA) for 24 hours to determine the optimum ATRA concentration to which the cells in question respond. Caco-2 cells were infected with recombinant adenoviruses carrying retinoic acid receptor beta (Ad-RARß) and small interfering RARß(siRARß) to assess the effects of RARß signalling on the expression of specific proteins. A siTLR4 lentivirus was used to knockdown Toll-like receptor 4 (TLR4) in Caco-2 cells to determine its role in the protective effects of VA on the intestinal epithelial barrier, and experiments involving TLR4-knock-out mice were performed to verify the effect of TLR4. VA normal (VAN), VAD and VAS rat models were established to confirm that changes in RARß, TLR4 and ZO-2 expression levels that occurred following decreases or increases in retinol concentrations in vivo, and the permeability of the Caco-2 cell monolayer, as well as that of the epithelial barrier of the rat intestine was detected by measuring transepithelial resistance (TER) or performing enzyme-linked immunosorbent assay (ELISA). Retinoic acid receptor (RAR), toll like receptor (TLR) and tight junction (TJ) mRNA and protein expression levels in Caco-2 cells and the colon monolayers in the rat and mouse models were measured by PCR and western blotting, respectively. Co-immunoprecipitation (co-IP) and immunofluorescence staining were performed to assess the interactions among RARß, TLR4 and zonula occluden-2 (ZO-2) in Caco-2 cells, and chromatin immunoprecipitation (ChIP) assay was performed to assess the binding between RARß and the TLR4 promoter sequence in Caco-2 cells. RESULTS: In the present study, ATRA treatment not only increased the TER of the Caco-2 monolayer but also up-regulated the expression levels of RARß, TLR4 and ZO-2 in Caco-2 cells. The expression levels of these three proteins were significantly decreased in the colonic epithelial monolayers of VAD rats compared with those of VAN rats and were significantly increased following VAS in the corresponding group compared with the control group. Furthermore, the above changes in TLR4 and ZO-2 expression levels were augmented or attenuated by Ad-RARß or siRARß infection, respectively, in Caco-2 cells. Interestingly, siTLR4 down-regulated ZO-2 expression but did not affect RARß expression in Caco-2 cells, and in VAD mice the lack of TLR4 did not affect ZO-2 expression. We noted direct interactions between RARß and TLR4, TLR4 and ZO-2 in Caco-2 cells, and ChIP assay showed that RARß could bind to the TLR4 promoter but not the ZO-2 promoter in Caco-2 cells. CONCLUSION: Taken together, our results indicate that RARß enhanced ZO-2 expression by regulating TLR4 to improve intestinal epithelial barrier function in Caco-2 cells, as well as in rat and mouse models, but not in humans.


Subject(s)
Intestines/drug effects , Receptors, Retinoic Acid/genetics , Toll-Like Receptor 4/genetics , Tretinoin/pharmacology , Zonula Occludens-2 Protein/genetics , Adenoviridae/genetics , Adenoviridae/metabolism , Animals , Caco-2 Cells , Gene Expression Regulation , Genetic Vectors/chemistry , Genetic Vectors/metabolism , Humans , Intestinal Mucosa/metabolism , Lentivirus/genetics , Lentivirus/metabolism , Mice , Mice, Knockout , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Rats , Receptors, Retinoic Acid/agonists , Receptors, Retinoic Acid/metabolism , Signal Transduction , Toll-Like Receptor 4/agonists , Toll-Like Receptor 4/metabolism , Transfection , Zonula Occludens-2 Protein/agonists , Zonula Occludens-2 Protein/metabolism
17.
Biomaterials ; 139: 102-115, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28599149

ABSTRACT

RNA interference (RNAi) and CRISPR-Cas9-based screening systems have emerged as powerful and complementary tools to unravel genetic dependencies through systematic gain- and loss-of-function studies. In recent years, a series of technical advances helped to enhance the performance of virally delivered RNAi. For instance, the incorporation of short hairpin RNAs (shRNAs) into endogenous microRNA contexts (shRNAmiRs) allows the use of Tet-regulated promoters for synchronous onset of gene knockdown and precise interrogation of gene dosage effects. However, remaining challenges include lack of efficient cloning strategies, inconsistent knockdown potencies and leaky expression. Here, we present a simple, one-step cloning approach for rapid and efficient cloning of miR-30 shRNAmiR libraries. We combined a human miR-30 backbone retaining native flanking sequences with an optimized all-in-one lentiviral vector system for conditional RNAi to generate a versatile toolbox characterized by higher doxycycline sensitivity, reduced leakiness and enhanced titer. Furthermore, refinement of existing shRNA design rules resulted in substantially improved prediction of powerful shRNAs. Our approach was validated by accurate quantification of the knockdown potency of over 250 single shRNAmiRs. To facilitate access and use by the scientific community, an online tool was developed for the automated design of refined shRNA-coding oligonucleotides ready for cloning into our system.


Subject(s)
Cloning, Molecular , Genetic Vectors/genetics , Lentivirus/genetics , MicroRNAs/genetics , RNA Interference , RNA, Small Interfering/genetics , Cell Line , Doxycycline/pharmacology , Gene Knockdown Techniques , Humans , Promoter Regions, Genetic
18.
Sci Rep ; 7(1): 604, 2017 04 04.
Article in English | MEDLINE | ID: mdl-28377587

ABSTRACT

The decrease of gelsolin (GSN) in the blood has been reported in multiple sclerosis (MS) patients and experimental allergic encephalomyelitis (EAE) animals, but the protective effect of GSN on EAE/MS lacks of evidence. In our study, we increased the GSN level in EAE by injecting GSN-overexpress lentivirus (LV-GSN) into the lateral ventricle and caudal vein and found that GSN administration can delay the onset and decrease the severity of EAE. Vitamin D is proven to have a therapeutic effect on MS/EAE; however, we previously found that vitamin D caused a downregulation of GSN, which might limit vitamin D efficacy. In our current research, we obtained a better symptom and a slowing down progression in EAE after combining vitamin D treatment with a proper increase of GSN. Furthermore, we discovered that the mediation of vitamin D on GSN might occur through the vitamin D receptor (VDR) by using gene interruption and overexpression to regulate the level of VDR in PC12 cells (a rat sympathetic nerve cell line). We also confirmed the anti-apoptotic function of GSN by GSN RNA interference in PC12. Collectively, these results support the therapeutic effect of GSN in EAE, which might enhance Vitamin D therapy in EAE/MS.


Subject(s)
Apoptosis/genetics , Encephalomyelitis, Autoimmune, Experimental/genetics , Gelsolin/genetics , Gene Expression , Multiple Sclerosis/genetics , Animals , Apoptosis/drug effects , Dietary Supplements , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/metabolism , Encephalomyelitis, Autoimmune, Experimental/pathology , Gelsolin/metabolism , Genetic Vectors/genetics , Humans , Lentivirus/genetics , Mice , Multiple Sclerosis/drug therapy , Multiple Sclerosis/metabolism , Multiple Sclerosis/pathology , Protein Binding , Rats , Receptors, Calcitriol/metabolism , Severity of Illness Index , Transduction, Genetic , Tumor Necrosis Factor-alpha/metabolism , Vitamin D/pharmacology , Vitamin D/therapeutic use
19.
J Pharmacol Sci ; 133(3): 130-138, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28258822

ABSTRACT

Abnormal store-operated calcium uptake has been observed in peripheral T lymphocytes of rheumatoid arthritis (RA) patients, and sustained intracellular calcium signalling is known to mediate the functions of many types of immune cells. Thus, it is hypothesized that regulating calcium entry through CRACM1 (the pore-forming subunit of calcium release-activated calcium (CRAC) channels; also known as ORAI1) may be beneficial for the management of RA. Localized CRACM1 knockdown in the joints and draining lymph nodes (DLNs) of mice with collagen-induced arthritis (CIA) was achieved via lentiviral-based delivery of shRNA targeting mouse CRACM1. Consistent with CRACM1 knockdown, calcium influx in synovial cells and the histopathological features of CIA were reduced. These effects were also associated with reduced levels of several notable inflammatory cytokines, such as IL-6, IL-17A, and IFN-γ, in the joints. Additionally, CRACM1-shRNA reduced the number of bone marrow-derived osteoclasts in vitro as well as osteoclasts in CIA joints, which was associated with reduced RANKL levels in the serum and joints. In summary, inhibiting calcium entry by CRACM1 knockdown suppressed arthritis development and may be therapeutically beneficial for RA patients.


Subject(s)
Arthritis, Experimental/therapy , Arthritis, Rheumatoid/therapy , Genetic Therapy , ORAI1 Protein/genetics , Animals , Arthritis, Experimental/blood , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/pathology , Cytokines/blood , Cytokines/immunology , Gene Silencing , Joints/immunology , Joints/pathology , Lentivirus/genetics , Lymph Nodes , Male , Mice, Inbred DBA , RANK Ligand/blood , RANK Ligand/immunology , RNA, Small Interfering/genetics , Spleen/cytology , Synovial Membrane/cytology
20.
Neuroreport ; 28(7): 367-374, 2017 May 03.
Article in English | MEDLINE | ID: mdl-28240720

ABSTRACT

To achieve neuronal differentiation of mouse bone mesenchymal stem cells (bMSCs) into neuron-like cells and explore the role of miR-122-5p that may regulate T-box brain 1 (Tbr1) expression during the induction. BMSCs were cultured and induced with butylated hydroxyanisole, retinoic acid (RA), basic fibroblast growth factor, and nerve growth factor in vitro. The cells were stained for neuron-specific enolase (NSE) and ß-III-tubulin by immunocytochemistry/immunofluorescence. MiR-122-5p that may regulate Tbr1 expression was predicted by bioinformatics and identified using a Dual-Luciferase assay. The expressions of miR-122-5p and Tbr1 were determined by real-time PCR and western blot before and after the induction. After infection of miR-122-5p, the expressions of Tbr1, NSE, and tauons were measured. BMSCs showed a short spindle shape with a uniform distribution. After 14 days, the induced cells showed neuronal traits with a pyramidal appearance. TargetScan and miRanda showed that miR-122-5p was well complementary with the target site of the Tbr1 3'-untranslated region. Identified by the Dual-Luciferase assay, we found that miR-122-5p could inhibit Tbr1 expression by binding to its 3'-untranslated region. Furthermore, the expressions of Tbr1 mRNA and protein were decreased by real-time PCR and western blot. Overexpression of miR-122-5p downregulated the expressions of Tbr1, NSE, and tauons. MiR-122-5p may negatively regulate Tbr1 expression to affect the differentiation of bMSCs into neuron-like cells.


Subject(s)
DNA-Binding Proteins/metabolism , Mesenchymal Stem Cells/metabolism , MicroRNAs/metabolism , Neurogenesis/physiology , Animals , Blotting, Western , Cells, Cultured , Flow Cytometry , Fluorescent Antibody Technique , Gene Expression , Genetic Vectors , Immunophenotyping , Lentivirus/genetics , Male , Mesenchymal Stem Cells/cytology , Mice, Inbred C57BL , MicroRNAs/genetics , Neurons/cytology , Neurons/metabolism , Phosphopyruvate Hydratase/metabolism , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , T-Box Domain Proteins , tau Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL